Information regarding the distribution of Xvivo Perfusion AB

In accordance with the resolution adopted by the Extraordinary General Meeting
of shareholders held on September 24, Vitrolife’s transplantation business,
which is run in the subsidiary Xvivo Perfusion AB (”Xvivo”) and its
subsidiaries, will be spun off to the shareholders through distribution of the
shares in Xvivo in accordance with “Lex Asea”.
The resolution means that the Vitrolife shareholders will automatically receive
one share in Xvivo for each share that they own in Vitrolife. The distribution
will not result in any tax effect for present Vitrolife shareholders as long as
they remain as owners of Xvivo. Allotment of the cost of acquisition for the
shares will be decided by the Swedish Tax Agency and will be published on
Vitrolife’s and Xvivo’s websites.

The last day for trade in Vitrolife shares with entitlement to distribution of
shares in Xvivo is September 26. The record day is October 1. It is estimated
that the Xvivo shares will have been booked in each shareholder’s VPC account by
October 4. Trade in Xvivo shares on NASDAQ OMX First North will begin on October
8. Before the listing Xvivo will publish a description of the company containing
detailed information about the company.

More information is available on Vitrolife’s and Xvivo’s websites,
www.vitrolife.com/corporate and www.xvivoperfusion.com
Queries should be addressed to:

Patrik Tigerschiöld, Chairman of the Board, phone 46 8 614 00 20
Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on
September 24, at 4.35 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global
biotechnology/medical device Group that works in the areas of Fertility and
Transplantation. The Fertility (http://www.vitrolife.com/en/Fertility/) product
area works with nutrient solutions (media), cryopreservation products and
advanced consumable instruments such as needles and pipettes, for the treatment
of human infertility. Work is also carried out to enable the use and handling of
stem cells for therapeutic purposes. The
Transplantation (http://www.xvivoperfusion.com/transplantation/) product area
works with solutions and systems for assessing and preserving organs outside the
body, so as to be able to select usable organs and keep them in optimal
condition pending transplantation.

Vitrolife (http://www.vitrolife.com/en/Corporate/) today has approximately 220
employees and its products are sold in almost 90 markets. The company is
headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife
share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on
NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/